TCF1+PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer
2022 · European Journal of Cancer · 56 citations
https://doi.org/10.1016/j.ejca.2022.07.004